Table S3.
Placebo | Galantamine | |
---|---|---|
Number of patients | 322 | 339 |
Total number of patients with condition* | 282 (87.6%) | 295 (87.0%) |
Allergic/immunologic | 7 (2.2%) | 13 (3.8%) |
Cardiovascular | 213 (66.1%) | 211 (62.2%) |
Dermatologic | 25 (7.8%) | 11 (3.2%) |
Endocrine and metabolic | 99 (30.7%) | 103 (30.4%) |
Eyes, ears, nose, and throat | 94 (29.2%) | 104 (30.7%) |
Gastrointestinal | 93 (28.9%) | 87 (25.7%) |
Genitourinary | 62 (19.3%) | 90 (26.5%) |
Hemopoietic/lymphatic | 11 (3.4%) | 12 (3.5%) |
Musculoskeletal | 102 (31.7%) | 113 (33.3%) |
Neurologic | 65 (20.2%) | 71 (20.9%) |
Psychiatric | 54 (16.8%) | 55 (16.2%) |
Respiratory | 33 (10.2%) | 38 (11.2%) |
Note:
Medical history and/or currently active condition.